BrainsWay Ltd. - American Depositary Shares (BWAY)
Frequently Asked Questions About BrainsWay Ltd. - American Depositary Shares (BWAY)
Does BrainsWay offer any training programs for practitioners?
Yes, BrainsWay provides extensive training programs and resources for healthcare practitioners who wish to implement dTMS therapy in their practices. This training ensures that practitioners understand how to use the technology effectively and provides them with clinical support and guidance.
How can patients find a provider of BrainsWay's therapies?
Patients looking for providers of BrainsWay's dTMS therapies can visit the company's official website, where they can locate certified treatment centers and clinics in their area. Additionally, healthcare providers often refer patients to facilities that utilize BrainsWay’s technology.
How does BrainsWay differentiate itself from competitors?
BrainsWay differentiates itself through its proprietary H7-Coil technology, which allows for deeper and broader stimulation of brain tissues compared to conventional TMS devices. This capability potentially increases treatment efficacy and provides a more comprehensive solution for patients with treatment-resistant depression or other disorders.
How does BrainsWay plan to address mental health needs globally?
BrainsWay is committed to addressing global mental health needs by expanding its international presence and forming strategic partnerships in various countries. By introducing its innovative dTMS technology worldwide, the company aims to make effective mental health treatment accessible to more patients suffering from psychiatric disorders.
How has BrainsWay performed in the stock market?
Since its listing on Nasdaq as BWAY, BrainsWay's stock performance has been closely monitored by investors. The performance is influenced by the company's clinical trial results, regulatory approvals, and market expansion efforts, reflecting investor confidence in its innovative solutions in mental healthcare.
How is dTMS therapy administered?
dTMS therapy is administered in a clinical setting, involving a series of outpatient sessions lasting about 20 to 40 minutes each. Patients are seated while a device is positioned over their head to deliver magnetic pulses safely and comfortably, targeting specific areas of the brain associated with mood regulation.
Is BrainsWay Ltd. publicly traded?
Yes, BrainsWay Ltd. is publicly traded on the Nasdaq stock exchange under the ticker symbol BWAY. The company was listed on the exchange to raise capital for further research and development of its dTMS technology and other psychiatric treatment solutions.
What are BrainsWay’s future goals?
BrainsWay aims to broaden its portfolio of mental health treatments, expand its market reach, and enhance patient access to its dTMS technology. The company is also focused on conducting further clinical research to support the efficacy of its treatments for additional psychiatric conditions.
What are the primary indications for dTMS therapy?
The primary indications for dTMS therapy include major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and treatment-resistant depression. The therapy is aimed at patients who have not found relief from conventional treatments, offering a new avenue for symptom management.
What clinical studies has BrainsWay conducted?
BrainsWay has conducted numerous clinical studies to evaluate the efficacy and safety of its dTMS technology for treating depression, OCD, and anxiety disorders. These studies have been pivotal in supporting the company’s claims and obtaining FDA clearances for its devices.
What does BrainsWay Ltd. do?
BrainsWay Ltd. is a medical technology company that focuses on developing advanced non-invasive treatments for mental health disorders. They specialize in Deep Transcranial Magnetic Stimulation (dTMS) therapy, which targets specific regions of the brain to alleviate symptoms of conditions such as depression, anxiety, and OCD.
What is Deep Transcranial Magnetic Stimulation (dTMS)?
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive neuromodulation technique that uses magnetic fields to stimulate nerve cells in the brain. It is primarily used for treating major depressive disorder and is designed to provide a therapeutic option for patients who have not responded to traditional treatments like medications.
What is the company's mission statement?
BrainsWay's mission is to transform the lives of patients with psychiatric disorders by providing innovative and effective non-invasive treatment options. The company is dedicated to advancing mental health care through research, development, and clinical collaboration.
What is the target market for BrainsWay?
The target market for BrainsWay includes mental health clinics, hospitals, and outpatient facilities that treat psychiatric disorders. They are focusing on expanding their presence in the U.S. market as well as internationally, offering innovative and effective solutions for individuals suffering from mental health issues.
What makes BrainsWay's technology unique?
BrainsWay's technology is unique due to its use of H7-Coil, designed for deep brain penetration and targeting specific brain regions not accessible by traditional TMS devices. This allows for more effective treatment of various psychiatric disorders, differentiating it from other neuromodulation techniques available.
What partnerships has BrainsWay established?
BrainsWay has formed various partnerships with healthcare institutions, research organizations, and clinical networks to enhance the reach of its dTMS therapy and contribute to ongoing research initiatives. These collaborations aim to advance understanding and applications of their technology in diverse treatment settings.
What regulatory approvals has BrainsWay obtained?
BrainsWay has received FDA clearance for its dTMS devices for the treatment of major depressive disorder and OCD. Additionally, the company has obtained various international certifications, allowing them to market and provide their devices in different countries around the world.
Where is BrainsWay Ltd. headquartered?
BrainsWay Ltd. is headquartered in Jerusalem, Israel. The company operates internationally, providing innovative mental health solutions and expanding its reach in various markets, including the United States.
What is the current price of BrainsWay Ltd. - American Depositary Shares?
The current price of BrainsWay Ltd. - American Depositary Shares is 8.318
When was BrainsWay Ltd. - American Depositary Shares last traded?
The last trade of BrainsWay Ltd. - American Depositary Shares was at 3:30 pm EDT on April 8th, 2025